Johnson & Johnson’s Tremfya gains FDA approval for Crohn’s disease, backed by Phase 3 trial data and demonstrating superiority over Stelara in key endpoints.
Johnson & Johnson’s Tremfya gains FDA approval for Crohn’s disease, backed by Phase 3 trial data and demonstrating superiority over Stelara in key endpoints.
Copyright © Louis Velazquez. All Rights Reserved.